Faculty Profiles - KANAZAWA Kenya

Papers - KANAZAWA Kenya

Division display141 - 160 of about 540／ All the affair displays >>

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022.5

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022.5

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022.5

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022.5

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022.5

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022.5

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022.5

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022.5

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022.5

Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.

Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Ishii T, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Kanbe T, Kanzaki N, Azuma T, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Tsukada Y, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Umeda T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Iseki K

International journal of medical sciences 19 ( 5 ) 834 - 841 2022（ ISSN:14491907 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

　 PREV - NEXT 　

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27